Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication.

{"title":"Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication.","authors":"David J Jackson, Girolamo Pelaia, Benjamin Emmanuel, Trung N Tran, David Cohen, Vivian H Shih, Anat Shavit, Douglas Arbetter, Rohit Katial, Adrian Paul J Rabe, Esther Garcia Gil, Marisa Pardal, Javier Nuevo, Michael Watt, Silvia Boarino, Sheena Kayaniyil, Claudia Chaves Loureiro, Alicia Padilla-Galo","doi":"10.1080/1750743X.2025.2457931","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2457931","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}